Morfina (Sem Conservantes) Labesfal (Morphine Hydrochloride Trihydrate)

Morphine acts as an agonist at mu‑opioid receptors in the brain and spinal cord. By activating these receptors, it inhibits the release of pain‑transmitting neurotransmitters, reduces neuronal excitability, and modulates descending pain pathways, resulting in decreased perception of pain and a sedative effect.

The appropriate dose of Morfina (Sem Conservantes) Labesfal is determined by the prescribing clinician based on the patient’s pain severity, prior opioid exposure, age, organ function, and route of administration. Dosage adjustments are made to achieve effective analgesia while minimizing adverse effects.

Safety data for morphine in pregnancy and lactation are limited. Opioids can cross the placenta and may be present in breast milk, potentially causing respiratory depression in the newborn. Use only if the benefit outweighs the risk and after consultation with a specialist.

To place an enquiry, visit the product page on gnhindia.com, enter the required quantity, and submit the request. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Morphine is considered the gold‑standard opioid for many types of severe pain due to its well‑characterized efficacy and pharmacokinetics. Compared with synthetic opioids such as fentanyl, morphine has a longer duration of action but may produce more pronounced gastrointestinal side effects. Choice of agent depends on clinical context, required onset, and patient-specific factors.

Morfina (Sem Conservantes) Labesfal should be stored at ambient temperature, preferably below 25 °C. Keep the vial in its original packaging, protect it from moisture, light, and extreme temperatures. Do not freeze. Follow standard aseptic handling procedures when preparing for injection.

The product is supplied as a sterile solution for injection. It can be given epidurally, intramuscularly, or intrathecally by a qualified healthcare professional using aseptic technique. The specific route, volume, and rate are determined by the prescriber based on the clinical indication.

The most critical risks include respiratory depression, severe hypotension, and life‑threatening allergic reactions such as anaphylaxis. These events require immediate medical attention. Monitoring of respiratory function, blood pressure, and signs of hypersensitivity is essential, especially during dose initiation and titration.

Patients with known hypersensitivity to morphine or any component of the formulation, those receiving monoamine oxidase inhibitors within 14 days, and individuals with severe respiratory insufficiency should avoid this medication. Caution is also advised for patients with uncontrolled asthma, severe head injury, or increased intracranial pressure.